Video Notes Flashcards: Autonomic Nervous System & Related Topics

Sympathetic and Parasympathetic Organization

  • Autonomic nervous system (ANS) consists of two divisions: Sympathetic (SNS) and Parasympathetic (PSNS).

  • SNS: Thoracolumbar outflow (preganglionic neurons originate from intermediolateral cell column, IML, at T1–L2).

  • PSNS: Craniosacral outflow (preganglionic neurons originate from CN III, VII, IX, X and S2–S4).

  • Ganglia locations:

    • SNS: ganglia near spinal cord (sympathetic chain); postganglionic neurons typically release norepinephrine (NE).

    • PSNS: ganglia near or within target organs; postganglionic neurons release acetylcholine (ACh).

  • Neurotransmitters:

    • Pre‑ganglionic: ACh (nicotinic Nn).

    • SNS postganglionic: NE (adrenergic).

    • PSNS postganglionic: ACh (muscarinic).

  • Organ effects summary (parasympathetic vs sympathetic):

    • Heart: SNS β1 ↑HR/contractility; PSNS M2 ↓HR/contractility.

    • Lungs: SNS β2 bronchodilation; PSNS M3 bronchoconstriction.

    • Eye: SNS α1 mydriasis; PSNS M3 miosis.

    • GI: SNS ↓ motility/secretions; PSNS ↑ motility/secretions.

    • Bladder: SNS relaxes detrusor, contracts sphincter; PSNS contracts detrusor, relaxes sphincter.

    • Sweat glands: SNS often via sympathetic cholinergic (M3); PSNS minimal direct effect.

  • Key high‑yield integration: receptor types dictate physiologic responses across organ systems.

Sympathetic Preganglionic Neurons and Ramus Anatomy

  • Origin: intermediolateral cell column (IML) from T1 to L2; limits sympathetic outflow to thoracolumbar region -> “thoracolumbar outflow.”

  • White rami communicantes: myelinated preganglionic fibers; located only T1–L2; connect spinal nerves to sympathetic chain ganglia.

  • Gray rami communicantes: unmyelinated postganglionic fibers; located at all spinal levels; allow postganglionic fibers to rejoin spinal nerves and reach structures via skin, sweat glands, arrector pili, blood vessels.

  • Function: entry of preganglionic fibers into the sympathetic chain and distribution to target organs.

Horner Syndrome: Superior Cervical Ganglion Lesion Clinical Signs

  • Horner syndrome = disruption of sympathetic supply to face/eye; parasympathetic system not involved.

  • Classic triad (PAM): Ptosis, Anhidrosis, Miosis (with optional Enophthalmos).

  • Lesion locations/causes include brainstem, T1 level, or superior cervical ganglion; classic association with Pancoast tumor compressing the T1 root.

  • Cocaine test blocks NE reuptake (no dilation) and hydroxyamphetamine helps localize lesion.

Pathway to the Eye and Face (Three-Neuron Arc)

  • 1) First-order neuron (central): start in hypothalamus → descend brainstem/spinal cord to T1.

  • 2) Second-order neuron (preganglionic): exits spinal cord at T1 → ascends in sympathetic chain to superior cervical ganglion.

  • 3) Third-order neuron (postganglionic): begins at superior cervical ganglion → follows carotid artery branches to eye, eyelids, sweat glands, and facial vasculature.

Parasympathetic Pathway to Lacrimal Gland

  • Goal: lacrimal gland tear production; PSNS promotes secretions.

  • Preganglionic origin: facial nerve (CN VII); specifically greater petrosal nerve carries parasympathetic fibers.

  • Pathway assembly: greater petrosal joins deep petrosal nerve → forms nerve of the pterygoid canal (Vidian nerve).

  • Synapse: preganglionic fibers synapse in the pterygopalatine ganglion (relay station).

  • Postganglionic path to lacrimal gland:

    • Hitchhike on branches of trigeminal nerve: first V2 (maxillary) then V1 (ophthalmic) via zygomatic nerve, finally reaching lacrimal nerve (branch of V1).

  • Outcome: stimulation of tear secretion by lacrimal gland.

Autonomic Toxidromes: Antimuscarinic, Cholinergic, Nicotinic

  • Antimuscarinic toxidrome (muscarinic blockade):

    • Causes: atropine, diphenhydramine, TCAs, antipsychotics, benztropine, etc.

    • Classic features: Dry (no sweating/saliva), Hot (hyperthermia), Blind (mydriasis/blurred vision), Red (flushed skin), Mad (delirium).

    • Other signs: urinary retention, constipation, tachycardia.

  • Cholinergic toxidrome (muscarinic excess):

    • Causes: organophosphates, carbamates, AChE inhibitors (donepezil, physostigmine).

    • Classic features (DUMBBELSS): Diarrhea, Urination, Miosis, Bronchorrhea, Emesis, Lacrimation, Salivation, Sweating, Sludge (bronchial secretions).

  • Nicotinic toxidrome (nicotinic overactivation):

    • Causes: organophosphates (nicotinic component), nicotine, succinylcholine.

    • Features: neuromuscular fasciculations/cramps → weakness, paralysis; autonomic effects (hypertension, tachycardia);

    • Note: secretions are muscarinic-dominant; nicotinic effects may not include secretions.

Vasovagal Syncope: Reflex Physiology

  • Vasovagal event: common cause of syncope due to abrupt autonomic shift.

  • Mechanism: ↑ parasympathetic (via vagus nerve) and ↓ sympathetic activity → bradycardia and vasodilation with hypotension; reduced cerebral perfusion leads to syncope.

  • Common triggers: emotional stress, prolonged standing, heat exposure, medical procedures, anxiety.

  • Reflex arc:

    • Trigger → brainstem autonomic centers misinterpret stress as requiring parasympathetic activation.

    • Parasympathetic surge (vagus) → bradycardia.

    • Sympathetic withdrawal → vasodilation, decreased SVR.

    • Net effect: ↓ CO and arterial pressure → transient loss of consciousness; rapid recovery when lying flat.

  • Clinical features: prodrome (nausea, dizziness, sweating), pale/cool skin, brief loss of consciousness, quick recovery due to restored venous return.

M3 Muscarinic Receptors: Tissue Responses

  • M3 receptor basics:

    • Type: Gq-coupled; located on smooth muscle, glands, endothelial cells.

    • Activation → ↑ IP3/DAG → ↑ intracellular Ca2+.

    • Core effect: “Wet and constricted.”

  • Tissue effects:

    • Eye: pupillary sphincter → contraction (miosis); ciliary muscle → accommodation.

    • Glands: salivary, lacrimal → secretions; sweat glands → sweating (sympathetic cholinergic, still via M3).

    • Lungs: bronchial smooth muscle constriction; bronchial glands ↑ mucus.

    • GI tract: increased motility and secretions.

    • Bladder: detrusor contraction; internal sphincter relaxation → easier voiding.

    • Blood vessels: endothelial M3 → NO release → vasodilation and BP decrease (indirect effect).

ACh-Induced Vascular Responses: Endothelium-Dependent vs Independent

  • Normal endothelium intact: ACh binds endothelial M3 → eNOS activation → NO production → smooth muscle relaxation → vasodilation (↓BP).

  • Damaged/denuded endothelium: no endothelial NO; ACh acts directly on vascular smooth muscle M3 → Ca2+ increase → contraction → vasoconstriction.

  • Clinical note: ACh can cause paradoxical vasospasm in diseased vessels with denuded endothelium.

α1 Receptor Pharmacology: Agonists and Blockade

  • α1 receptors on vascular smooth muscle (arterioles, venous smooth muscle): Gq → ↑ IP3/DAG → ↑ Ca2+ → contraction → vasoconstriction.

  • α1 agonists:

    • Examples: Phenylephrine, norepinephrine (α1 component), midodrine.

    • Effects: ↑ PVR, ↑ venous tone, ↑ BP.

    • Reflex effect: baroreceptors trigger parasympathetic activity → reflex bradycardia.

  • α1 blockade:

    • Drugs: Prazosin, doxazosin, phenoxybenzamine, phentolamine.

    • Effects: vasodilation, ↓ BP; venodilation → ↓ venous return → orthostatic hypotension.

    • Reflex effect: baroreceptors trigger sympathetic activation → reflex tachycardia.

Presynaptic α2 Autoreceptors and Yohimbine Reversal

  • Presynaptic α2 autoreceptors: brake on NE release from sympathetic nerve endings.

  • Mechanism: NE binds α2 → Gi activation → ↓ cAMP → ↓ Ca2+ entry → less NE release.

  • α2 agonists (e.g., clonidine) strengthen brake → less NE → weaker NE effects on α1.

  • Yohimbine: α2 antagonist → blocks the brake → increases NE release.

  • Outcome in vas deferens: more NE → more α1 contraction; Yohimbine reverses α2 brake to restore contraction.

β2 Receptors and Airway Smooth Muscle; β-Blocker Antagonism

  • β2 receptor basics: Gs → ↑ cAMP → PKA activation → ↓ intracellular Ca2+ → smooth muscle relaxation.

  • β2 agonists (e.g., albuterol, salmeterol, terbutaline, formoterol): bronchodilation; used in asthma/COPD; SABA for rescue, LABA for maintenance with inhaled corticosteroids.

  • β-blocker antagonism: nonselective blockers (e.g., propranolol, nadolol, timolol) block β2 → risk of bronchoconstriction in asthma/COPD; β1-selective blockers (metoprolol, atenolol, bisoprolol) are safer but at higher doses may lose selectivity.

Dale’s Vasomotor Reversal (Epinephrine after α-Blockade)

  • Normal epinephrine action: binds α1 (vasoconstriction) and β2 (vasodilation); net effect depends on dose/location; often ↑ systolic BP with slight diastolic dip due to β2 effects.

  • After irreversible α-blockade (e.g., phenoxybenzamine): α1 vasoconstriction blocked; β2 vasodilation remains unopposed.

  • Epinephrine administration in this state causes a fall in BP due to unopposed β2-mediated vasodilation: Dale’s vasomotor reversal.

  • Clinical relevance: explains paradoxical BP drop after epinephrine in patients on α-blockers (pheochromocytoma management, MAOIs, etc.).

Low-Dose Epinephrine Hemodynamics

  • At low dose, β effects dominate over α effects.

  • Receptor effects:

    • β1 (heart): ↑ SA node firing → ↑ HR; ↑ contractility → ↑ systolic BP.

    • β2 (skeletal muscle vasculature): Vasodilation → ↓ diastolic BP.

  • Hemodynamic pattern:

    • Systolic BP up; Diastolic BP down; Pulse pressure widened; HR up.

    • MAP may be unchanged or slightly increased; reflexes may be blunted due to vasodilation in some beds.

Norepinephrine Hemodynamics (α1 + β1 dominant, β2 weak)

  • Receptor selectivity: strong α1 vasoconstriction; strong β1 increases inotropy/chronotropy; β2 minimal.

  • Hemodynamics:

    • Systolic BP rises (β1-driven ↑ contractility) and diastolic BP rises (α1 vasoconstriction).

    • MAP rises significantly; reflex bradycardia occurs due to baroreceptor activation given high BP.

MAOI–Tyramine Hypertensive Crisis: Phentolamine for Management

  • Tyramine in foods (aged cheese, red wine, cured meats) is normally degraded by MAO; with MAOI, tyramine enters sympathetic nerve endings and releases large NE leading to hypertensive crisis.

  • Treatment: IV phentolamine (nonselective, reversible α1/α2 blocker) induces vasodilation to rapidly lower BP.

  • Clinical contexts: pheochromocytoma, cocaine-induced hypertension as well.

Labetalol for Rapid IV Blood Pressure Control in Pregnancy

  • Clinical problem: pregnant patient with severe HTN (preeclampsia/eclampsia).

  • Labetalol properties: mixed α1 and β receptor blockade.

    • α1 blockade → vasodilation → ↓ systemic vascular resistance.

    • β1 blockade → slows heart rate and reduces contractility → ↓ cardiac output.

  • Advantage: rapid BP reduction without reflex tachycardia due to β-blockade dampening the reflex.

  • Alternative safe options in pregnancy include hydralazine, methyldopa, nifedipine; avoid ACE inhibitors/ARBs.

Master Study Guide: Integrative Concepts for ANS & Pharmacology

  • Adrenergic receptors functions:

    • α1: vasoconstriction; SNA tone; vascular smooth muscle.

    • α2: presynaptic inhibition of NE release; feedback control.

    • β1: heart (inotropy/chronotropy); kidney renin release.

    • β2: bronchodilation, vasodilation in skeletal muscle, uterine relaxation.

    • β3: lipolysis, bladder relaxation (not heavily emphasized in this deck).

  • GPCR signaling types:

    • Gs: ↑ cAMP (β receptors, certain dopaminergic receptors).

    • Gi: ↓ cAMP (α2, some M2 receptors).

    • Gq: ↑ IP3/DAG → Ca2+ signaling (α1, M3, H1, V1).

  • Signaling pathways: GPCRs, RTKs (e.g., insulin receptor), JAK/STAT, serine/threonine kinases; intracellular receptors (steroids).

  • Direct vs indirect sympathomimetics; indirect agents increase NE release or inhibit reuptake.

  • Catecholamine synthesis and breakdown: Tyrosine → DOPA → Dopamine → NE → Epi; MAO/COMT metabolize catecholamines to VMA.

  • Reflexes: α1 agonists trigger reflex bradycardia; β2 agonists trigger reflex tachycardia; ganglion blockers abolish reflexes.

  • Pregnancy-associated hypertension management: Labetalol; alternative safe drugs include hydralazine, methyldopa, nifedipine.

  • Poisoning management: Atropine for antimuscarinic/cholinergic toxidromes; pralidoxime for cholinesterase inhibitors; phentolamine for MAOI–tyramine crises.

  • Tests for Horner localization: cocaine vs hydroxyamphetamine; Pancoast tumor association with T1 root.

Tissue Bases: Extracellular Matrix (ECM) and Basal Lamina

  • ECM components and roles:

    • Collagen: provides strength; key amino acids Glycine every third residue; Proline/hydroxyproline promote helix; Vitamin C needed for collagen hydroxylation; disulfide bonds stabilize triple helix.

    • Elastin: provides elasticity; rich in proline/glycine; cross-linking.

    • Proteoglycans: hydrated, resist compression; GAGs covalently linked to core proteins; Hyaluronan forms backbone of proteoglycan matrices; strong for joint lubrication.

    • Fibrillin: essential for elastic fiber assembly; Marfan syndrome via fibrillin mutations.

  • Basal lamina: structural support and selective barrier; laminin anchors epithelia; heparan sulfate proteoglycans (HSPGs) regulate filtration and growth; in hyperglycemia, HSPGs degrade affecting renal filtration.

  • Tissue defects: collagen and ECM mutations/diseases (OI, EDS, Alport, Goodpasture, EB types) produce systemic connective tissue problems.

Collagenopathies and Related Connective Tissue Disorders (Summary)

  • Osteogenesis imperfecta: type I collagen gene mutations; bone fragility.

  • Ehlers-Danlos syndrome: defective collagen types I, III, V; hyperextensible joints; fragile skin.

  • Alport syndrome: type IV collagen mutation; nephritis and hearing loss.

  • Goodpasture syndrome: autoantibodies against type IV collagen; renal and pulmonary basement membrane injury.

  • Epidermolysis bullosa: keratin or laminin/integrin defects; skin fragility.

  • Dystrophic EB: collagen VII defect; skin and mucosal fragility.

  • Marfan syndrome (fibrillin defect): aortic root dilation and ocular issues.

Cell Interactions and Adhesion Molecules

  • Fibronectin: stabilizes cell adhesion to ECM; guides cell shape, growth direction, migration, wound healing.

  • Integrins: mediate focal adhesion; bind to actin stress fibers; signal transduction.

  • Hemidesmosomes: integrins binding to intermediate filaments.

  • Cadherins: cell-cell adhesion via actin cytoskeleton (catenins).

  • Bullous pemphigoid: autoantibodies to hemidesmosomes; pemphigus vulgaris: desmosomal defects.

  • RAC and RHO: small GTPases control cytoskeletal rearrangements and focal adhesions during cell movement.

Signal Transduction: Key Pathways Overview

  • Intracellular signaling proteins:

    • Kinases, GTPases.

  • Cell surface receptors:

    • GPCRs, receptor tyrosine kinases (e.g., Ras-MAPK), serine/threonine kinases, JAK/STAT, ion-channel linked receptors.

  • GPCR signaling schemes:

    • Gs → ↑ cAMP → PKA activation.

    • Gi → ↓ cAMP.

    • Gq → ↑ IP3/DAG → ↑ Ca2+.

  • Bacterial toxins and signaling:

    • Cholera toxin: locks Gs in active state (↑ cAMP).

    • Pertussis toxin: locks Gi in inactive state (↑ cAMP).

  • RTK pathway (Ras-MAPK): Grb2 -> SOS -> Ras activation -> MAPK cascade.

  • Steroid hormone signaling: nuclear receptors (estrogen, progesterone, glucocorticoids).

pH, Acids, and Buffering: Henderson–Hasselbalch and Acid–Base Disorders

  • Henderson–Hasselbalch equation: pH=pKa+ log⁡([A−][HA])pH = pK_a + \, \log \left( \frac{[A^-]}{[HA]} \right)

  • Acids vs bases terminology; pKa defines strength; smaller pKa = stronger acid.

  • Acidemia vs alkalemia: arterial pH thresholds: acidemia < 7.35; alkalemia > 7.45.

  • Metabolic vs respiratory disorders:

    • Metabolic acidosis/alkalosis: low/high HCO3−; compensatory changes in PCO2 via respiration.

    • Respiratory acidosis/alkalosis: abnormal PCO2; renal/metabolic compensation.

  • Notable patterns:

    • Anion gap calculations (not explicitly listed, but implied in metabolic acidosis workup).

Glycolysis, Pyruvate, and TCA Cycle: Core Metabolism Essentials

  • Glycolysis overview (key steps and control points):

    • Step 1: Glucose → glucose-6-phosphate (hexokinase); irreversible; consumes 1 ATP (rate-limiting).

    • Step 3: Fructose-6-phosphate → fructose-1,6-bisphosphate (PFK-1); irreversible; consumes 1 ATP (rate-limiting).

    • Step 6: G3P → 1,3-BPG (G3PD); generates 2 NADH.

    • Step 7: 1,3-BPG → 3-PG (phosphoglycerate kinase); substrate-level phosphorylation; yields 2 ATP.

    • Step 10: PEP → pyruvate (pyruvate kinase); substrate-level phosphorylation; yields 2 ATP.

    • Shuttle systems: glycerol-3-phosphate shuttle (brain, skeletal muscle) yields ~30 ATP; malate-aspartate shuttle yields ~32 ATP.

  • Pyruvate fate decisions:

    • Pyruvate → acetyl-CoA via pyruvate dehydrogenase (PDH) complex; links glycolysis to TCA; regulated by NAD+/NADH, acetyl-CoA, Ca2+, and vitamin cofactors (B1, B2, B3, B5).

    • Pyruvate can convert to lactate (lactate dehydrogenase), oxaloacetate (pyruvate carboxylase), alanine (alanine transaminase), ethanol (in microbes).

  • Pyruvate dehydrogenase complex (PDH): requires thiamine (B1, TPP), lipoate, FAD, NAD+, CoA; active with insulin, NAD+, CoA, Ca2+; inhibited by acetyl-CoA, NADH, ATP, high cAMP, arsenic; deficiency causes lactic acidosis and neurodevelopmental issues.

  • TCA cycle highlights (rate-limiting steps and key enzymes):

    • Isocitrate → α-ketoglutarate: isocitrate dehydrogenase (rate-limiting, produces NADH).

    • α-KG → succinyl-CoA: α-ketoglutarate dehydrogenase complex (produces NADH).

    • Succinyl-CoA → succinate: succinyl-CoA synthetase (GDP → GTP).

    • Succinate → fumarate: succinate dehydrogenase (complex II; produces FADH2).

    • Malate → oxaloacetate: malate dehydrogenase (produces NADH).

  • TCA inhibitors and irreversible steps listed (e.g., citrate synthase, isocitrate dehydrogenase, α-KG dehydrogenase).

  • ETC overview: oxidative phosphorylation drives ~90% of ATP; substrate-level phosphorylation in cytosol ~10%.

  • Clinical notes: hypoxia → lactic acidosis; statins impact CoQ and mitochondrial function; cytochrome c release → apoptosis; various inhibitors affect complexes I–IV.

Glycogen Storage Diseases: Overview and Examples

  • Glycogen storage disorders involve abnormal glycogen metabolism.

  • Key diseases and enzyme defects:

    • Von Gierke disease: glucose-6-phosphatase deficiency; severe hypoglycemia, hepatomegaly, lactic acidosis.

    • Pompe disease: acid maltase (alpha-1,4-glucosidase) deficiency; cardiomegaly and muscle weakness.

    • Cori disease (debranching enzyme deficiency): milder hypoglycemia, hepatomegaly.

    • Andersen disease (branching enzyme deficiency): infantile hypotonia, cardiomyopathy, cirrhosis.

    • McArdle disease (muscle glycogen phosphorylase deficiency): muscle cramps with exercise, myoglobinuria.

    • Hers disease (liver glycogen phosphorylase deficiency): hypoglycemia, hepatomegaly.

  • Mnemonic: “PAM does not have hypoglycemia” (per page 28-29) as a study cue.

Gluconeogenesis: Substrates, Pathways, and Control

  • Substrates: lactate, glucogenic amino acids, glycerol, odd-chain fatty acids.

  • Cori cycle: lactate ↔ glucose cycling between peripheral tissues and liver.

  • Cahill cycle: alanine ↔ glucose cycling between liver and muscle.

  • Key steps:

    • Pyruvate → oxaloacetate → phosphoenolpyruvate (PEP) via pyruvate carboxylase (requires biotin + CO2) and PEP carboxykinase (PEPCK) (uses 1 ATP and 1 GTP respectively).

    • Fructose-1,6-bisphosphate → fructose-6-phosphate via FBPase-1 (rate-limiting step).

    • Glucose-6-phosphate → glucose via glucose-6-phosphatase.

  • Regulation:

    • Pyruvate carboxylase activated by acetyl-CoA; inhibited by ADP.

    • PEPCK regulated by glucagon, epinephrine, cortisol; inhibited by insulin.

    • FBPase-2 activity and F2,6BP levels regulate PFK-1 and gluconeogenesis (low F26BP favors gluconeogenesis; high F26BP favors glycolysis).

  • Pyruvate carboxylase deficiency leads to reduced OAA, impaired TCA and gluconeogenesis, shunting to lactate; treatment with biotin.

HMP Shunt (Pentose Phosphate Pathway)

  • Generates NADPH (oxidative branch) and ribose-5-phosphate for nucleotide synthesis (non-oxidative branch can interconvert sugars).

  • Key enzymes: G6PD (rate-limiting in oxidative phase); transketolase (requires TPP/B1); transaldolase (non-oxidative).

  • NADPH is required for reductive biosynthesis and glutathione reduction (antioxidant defense).

  • Clinical correlations:

    • G6PD deficiency → susceptibility to oxidative stress; Heinz bodies; hemolysis.

    • Chronic granulomatous disease arises from NADPH oxidase defects, impairing microbial killing.

  • Malaria/antimalarial drugs can affect NADPH and oxidative stress pathways.

Metabolic and Immune System Sections (Overview)

  • Essential immune components:

    • Chemokines attract cells to tissues via chemokine receptors.

    • Cytokines (e.g., IL-3, GM-CSF, G-CSF, M-CSF, IL-5) promote proliferation and differentiation of immune lineages.

    • Primary lymphoid tissues: bone marrow and thymus; secondary lymphoid tissues include spleen, lymph nodes, tonsils, adenoids, appendix, Peyer’s patches; mucosal-associated lymphoid tissue.

    • Innate immunity: alternative pathway of complement via C3b deposition.

    • Adaptive immunity: complement classical pathway activated by antibody binding.

  • Basic inflammatory and immune signaling (brief): chemokines and cytokines guide immune cell traffic and activation; GPCR, RTK, JAK/STAT signaling underlie many immune responses.

Pharmacodynamics: Basic Concepts and Receptor Pharmacology

  • Pharmacodynamics = what the drug does to the body; dose–response relationships, receptor interactions, and downstream effects.

  • Key terms:

    • Agonist: activates receptor.

    • Pharmacologic antagonist: binds receptor and blocks activation.

    • Physiologic antagonist: binds different receptor to oppose effect.

    • Chemical antagonist: binds to agonist, reducing effect.

    • Constitutive activity: receptor activity in absence of ligand.

    • Inverse agonist: stabilizes inactive receptor state; reduces constitutive activity.

  • Receptor types:

    • Ion-channel receptors (ligand-gated channels).

    • GPCRs (G-protein-coupled receptors).

    • Enzyme-linked receptors (e.g., receptor tyrosine kinases).

    • Intracellular receptors (nuclear receptors).

  • GPCR signaling families (illustrative):

    • Gs → increases cAMP → activates PKA.

    • Gi → decreases cAMP.

    • Gq → increases IP3 and DAG → increases Ca2+.

    • G12/13 → Rho family signaling.

  • Desensitization and tolerance:

    • Downregulation: receptor internalization/degradation.

    • Tachyphylaxis: receptor phosphorylation leading to reduced responsiveness.

    • Upregulation: increased receptor number due to antagonist or absence of agonist.

  • Pharmacokinetics interplay (brief): pharmacokinetics informs pharmacodynamics via drug exposure, but see dedicated PK section.

Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion (ADME)

  • Ionization and absorption:

    • Nonionized (lipid-soluble) drugs cross membranes easily; ionized (water-soluble) do not.

    • pH partitioning and pKa determine ionization state; ion trapping manipulates excretion.

    • Acidic drugs trapped in basic urine; basic drugs trapped in acidic urine (clinical poison management).

  • Bioavailability (F): fraction of an administered dose reaching systemic circulation.

    • For IV administration, F = 1.

    • F = f × (1 − ER); ER = extraction ratio = CL_liver / Q.

    • Bioequivalence: two products with equivalent rate and extent of absorption.

  • First-pass effect: hepatic and gut wall metabolism before reaching systemic circulation; routes to bypass include sublingual, rectal, and transdermal.

  • Absorption parameters:

    • Cmax, Tmax describe rate and extent of absorption.

  • Volume of distribution (Vd): distribution of a drug between plasma and body compartments.

    • Vd = (amount of drug in the body) / (plasma drug concentration).

    • Typical values/interpretation:

    • Vd < 4 L: mostly confined to blood/plasma.

    • ~14 L: distributed between plasma and interstitial fluid.

    • Vd > 42 L: wide distribution into tissues; long half-life potential.

  • Clearance (CL): rate of elimination relative to plasma concentration.

    • CL = (rate of elimination) / (plasma concentration).

    • First-order kinetics: clearance constant; elimination proportional to concentration; most drugs follow this.

    • Zero-order kinetics: elimination rate is constant irrespective of concentration (e.g., aspirin at high doses, alcohol, phenytoin).

  • Half-life (t1/2): time for plasma concentration to fall by half.

    • t<em>1/2=rac0.693imesV</em>dCLt<em>{1/2} = rac{0.693 imes V</em>d}{CL}

    • Steady-state concentration (Css) is achieved after ~5 half-lives; Css proportional to dose and inversely proportional to clearance.

    • Css=racDoseimesFCLimestC_{ss} = rac{Dose imes F}{CL imes t} where t is dosing interval.

  • Loading dose concept:

    • Loading dose = Vd × C_target (variant shown as Vd × Tc in some notes), used to rapidly achieve therapeutic concentration.

  • Drug–protein binding: competition for albumin can displace drugs, increasing free (active) drug fraction.

  • P-glycoprotein and CYP interactions:

    • Inducers: rifampin, St. John’s wort; inhibit or induce hepatic metabolism and may alter drug levels.

    • Inhibitors: grapefruits, amiodarone, cimetidine, ciprofloxacin, ritonavir; can raise levels of coadministered drugs.

  • First-pass vs alternative routes summary:

    • Sublingual and transdermal routes avoid first-pass metabolism; rectal offers partial bypass.

Pharmacokinetics: Special Concepts and Calculations

  • Volume of distribution notes:

    • Small Vd indicates confinement to plasma; large Vd indicates tissue distribution.

  • Loading dose rationale and calculation notes.

  • Bioavailability and extraction ratio concepts, including liver extraction considerations.

  • First-pass effect and strategies to bypass it.

  • Drug interactions due to transporter (P-gp) and CYP enzyme modulation.

Clinical Highlights: High‑Yield Integrations and Mnemonics

  • Adrenergic receptor summary:

    • α1 squeezes vessels (vasoconstriction);

    • α2 brakes NE release;

    • β1 heart and kidney (β1 ↑HR/contractility; renin);

    • β2 lungs, skeletal muscle vasodilation, uterine relaxation.

  • GPCR signaling fundamentals: Gs (cAMP), Gi (↓ cAMP), Gq (Ca2+ via IP3/DAG).

  • Contrast of epinephrine vs norepinephrine patterns in hemodynamics and reflexes (α vs β effects).

  • Hormonal regulation basics: insulin and glucagon balance metabolic pathways in liver and peripheral tissues.

  • Common drug safety concepts: therapeutic index, therapeutic window, efficacy, potency, and spare receptors.

  • Pregnancy pharmacology: select antihypertensives that are safer in pregnancy (labetalol, hydralazine, methyldopa, nifedipine).

Appendix: Enzyme Cofactors, Vitamins, and Deficiencies (Biochem Reference)

  • Key vitamins and coenzymes:

    • B1 (thiamine, TPP): PDH, branched-chain dehydrogenases; Beriberi (wet/dry); Wernicke-Korsakoff.

    • B2 (riboflavin, FAD/FMN): redox reactions.

    • B3 (niacin, NAD+/NADP+): redox reactions.

    • B5 (pantothenic acid): CoA formation.

    • B6 (pyridoxine, PLP): transaminases.

    • B7 (biotin): carboxylases.

    • B9 (folate): thymidylate synthesis; THF.

    • B12 (cobalamin): methylation and odd-chain metabolism.

  • Clinically relevant metabolic disorders appear in the context of deficiencies and genetic defects (e.g., PKU, homocystinuria, glycogen storage diseases, porphyrias, urea cycle defects).

References to Equations and Quantitative Concepts (Summary)

  • Henderson–Hasselbalch (acid–base and ion trapping):

    • pH=pKa+ log⁡([A−][HA])pH = pK_a + \, \log \left(\frac{[A^-]}{[HA]}\right)

    • Weak acid: Ionization increases with pH; weak base: ionization increases with lower pH.

  • Pharmacokinetics:

    • Bioavailability: F=f×(1−ER)1F = \frac{f \times (1 - ER)}{1}

    • ER (extraction ratio): ER=CLliverQER = \frac{CL_{liver}}{Q}

    • Clearance: CL=Rate of eliminationCpCL = \frac{\text{Rate of elimination}}{C_p}

    • Volume of distribution: V<em>d=AC</em>pV<em>d = \frac{A}{C</em>p}

    • Half-life: t<em>1/2=0.693⋅V</em>dCLt<em>{1/2} = \frac{0.693 \cdot V</em>d}{CL}

    • Steady-state concentration: approximately after 5 t1/25 \, t_{1/2}

    • Maintenance dose: Maintenance dose=Css×CL×t\text{Maintenance dose} = C_{ss} \times CL \times t

    • Loading dose: Loading dose=V<em>d×C</em>ss\text{Loading dose} = V<em>d \times C</em>{ss} (some sources use target concentration, noted as Tc/Css)

  • pH/pKa ion trapping conventions:

    • Acidic drugs become more ionized in basic environments; basic drugs become more ionized in acidic environments.

    • Practical clinical note: adjust urine pH to enhance excretion of toxicants via ion trapping.

Quick-Reference: Key Topics by Page (Condensed Mapping)

  • Page 1–2: Sympathetic preganglionic origin (T1–L2), white/gray rami anatomy, thoracolumbar outflow.

  • Page 3–5: Horner syndrome pathophysiology, signs, lesion levels, diagnostic tests.

  • Page 6–7: Parasympathetic lacrimal pathway, pterygopalatine ganglion, trigeminal hitchhike.

  • Page 8–9: Toxidromes—antimuscarinic, cholinergic, nicotinic.

  • Page 10–11: Vasovagal reflex physiology and clinical features.

  • Page 12–13: M3 receptor tissue effects; endothelium NO mechanism with intact vs denuded endothelium.

  • Page 14–15: α1 receptor pharmacology (agonists vs blockers) and reflexes.

  • Page 16–17: Presynaptic α2 autoreceptors, clonidine effect, yohimbine reversal.

  • Page 18–19: β2 receptor agonists for airway; β-blocker implications.

  • Page 20–21: Dale’s vasomotor reversal; clinical relevance.

  • Page 22–25: Low-dose epinephrine vs norepinephrine hemodynamics; pregnancy safety and crisis management.

  • Page 26–29: Master study guide integrative points; horner localization cues; lacrimal pathway recapped; vasovagal syncope recap.

  • Page 30–33: ECM components, basal lamina, laminin, proteoglycans; cell junctions; signaling basics.

  • Page 34–36: Diffusion basics; pH and enzymes; pharmacodynamics overview.

  • Page 37–41: Carbohydrate metabolism and transport; pyruvate fate; PDH and deficiency notes; vitamin deficiencies.

  • Page 42–46: TCA cycle and inhibitors; PPP; glycogen disorders; gluconeogenesis.

  • Page 47–53: Non-glucose sugar metabolism; lysosomal storage diseases; urea cycle disorders; amino acid metabolism.

  • Page 53–60: Immune system basics; pharmacodynamics; pharmacokinetics fundamentals.

  • Page 61–67: Ion trapping, bioavailability, first-pass effect; metabolism (CYPs, UGTs, GSTs, SULTs, NATs); PK concepts; half-life and steady state.